An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen

This study is to determine the highest dose of Eltrombopag that is safe and that will work the best to minimize thrombocytopenia, or low platelets that occur during Adriamycin and Ifosfamide for sarcoma. To be eligible, platelets must have been below 75,000 on a previous chemotherapy, or during current treatment of Adriamycin and Ifosfamide.  Eltrombopag is taken by mouth daily only during certain days of the chemotherapy cycle.